TITLE:
Treatment of Chronic Oxaliplatin-Induced Peripheral Neuropathy: A Systematic Review
AUTHORS:
Alda Tavares, Ana Agrelo, Manuela Machado
KEYWORDS:
Peripheral Neuropathy, Oxaliplatin, Chemotherapy-Induced Peripheral Neuropathy, Pain, Neurotoxicity, Supportive Care
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.11 No.9,
September
16,
2020
ABSTRACT: Introduction: Oxaliplatin is a platinum-derivative chemotherapeutic agent used in
digestive tumours, in the adjuvant and metastatic setting. Oxaliplatin can
cause a chronic peripheral sensory neuropathy which impacts the quality of life and is
dose limiting. To date, no therapeutic strategies have proved effective in the
treatment of oxaliplatin-induced peripheral neuropathy (OIPN). Methods: A
computerized search of the literature on PubMed database was performed.
Publisher original articles were included if they focused on treatment of
peripheral neuropathy among patients submitted to oxaliplatin. Eleven out of
242 reviewed papers met our inclusion criteria and were subjected to a 19-item
quality checklist. Results: The included studies differed with respect
to study design, patient population and sample size, neuropathic symptoms
assessment and efficacy measure. Most studies had an adequate quality. Ten trials tested one drug, and
one pilot study tested a non-pharmacological treatment—the neurofeedback. Of these, 3 trials included only
patients submitted to oxaliplatin-based chemotherapy. Duloxetine showed
moderate efficacy in 3 trials. Topical treatment with capsaicin or 10%
amitriptyline was promisors in 2 single-arm trials with a few samples. Conclusion: In the
last decade, there wasn’t an
improvement in the treatment of chronic OIPN. The duloxetine is the unique drug
with moderate efficacy on the treatment of OIPN. There is insufficient evidence
to support a recommendation for any other treatment.